SERVICES________________

SELECT ISSUER CLIENTS

Neubase  

NeuBase Therapeutics

NeuBase Therapeutics, Inc. is developing its modular peptide-nucleic acid antisense oligonucleotide (PATrOL™) platform to address genetic diseases caused by mutant proteins with a single, cohesive approach. The systemically-deliverable PATrOL therapies will improve upon current gene silencing treatments by combining the advantages of synthetic approaches with the precision of antisense technologies. NeuBase will use its platform to address repeat expansion disorders, with an initial focus on Huntington’s Disease and Myotonic Dystrophy, as well as other dominant genetic disorders.

VIEW WEBSITE
     
   

ZyVersa Therapeutics

ZyVersa Therapeutics (formerly Variant Pharmaceuticals) is a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs. ZyVersa’s focus is on patients with inflammatory and renal diseases who have high unmet medical needs. The company’s clinical pipeline includes phase 2a-ready VAR 200, a cholesterol efflux mediator for treatment of an orphan renal disease, focal segmental glomerulosclerosis (FSGS), and a novel inflammasome inhibitor with potential for multiple inflammatory diseases.

VIEW WEBSITE
 

TherapeuticsMD*

TherapeuticsMD, Inc. operates as a women’s health care product company. The company manufactures and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, and natural menopause relief products under the vitaMedMD brand, as well as generic formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. The company markets its products primarily through a direct national sales force to health care providers in the OB/GYN market space. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

VIEW WEBSITE


 
   
 

Cynapsus*

Cynapsus is a specialty pharmaceutical company developing the only oral (sublingual) delivery of the only approved drug (apomorphine) to treat the motor symptoms of Parkinson’s disease. Cynapsus’ lead drug candidate, APL-130277, is an easy-to-administer, fast-acting and oral reformulation of an approved drug, apomorphine, used to rescue patients from “off” episodes. Cynapsus Therapeutics was acquired in November 2016 by Sunovion Pharmaceuticals, Inc.

VIEW WEBSITE

     
     

 

* Selected issuer client transactions led by Allele’s Principals while employed at prior investment banks.